Commitments and Contingencies (Details Narrative) - USD ($) |
9 Months Ended | ||||||
|---|---|---|---|---|---|---|---|
Jun. 01, 2026 |
Dec. 15, 2024 |
May 01, 2021 |
Sep. 13, 2016 |
Sep. 30, 2026 |
Sep. 30, 2025 |
Dec. 31, 2025 |
|
| Loss Contingencies [Line Items] | |||||||
| Operating lease term | 76 months | 61 months | |||||
| Base rent | $ 3,650 | $ 3,783 | |||||
| Operating lease yearly escalation percentage | 3.00% | 3.00% | |||||
| Operating lease right-of-use asset | $ 211,070 | $ 23,214 | |||||
| Lease liability | $ 225,049 | ||||||
| Borrowing rate | 8.00% | ||||||
| Pharm Ala Biotech Holdings Inc. [Member] | |||||||
| Loss Contingencies [Line Items] | |||||||
| Commercialization milestone payments description | The Company is also obligated to make commercialization milestone payments totaling up to $73,333,333, consisting of (i) $10,000,000 upon achieving $333,333,333 in net sales, (ii) $30,000,000 upon achieving $1,000,000,000 in net sales, and (iii) $33,333,333 upon achieving $2,000,000,000 in net sales. Each milestone payment is payable only once upon achievement of the applicable milestone. | ||||||
| Consulting Agreements [Member] | |||||||
| Loss Contingencies [Line Items] | |||||||
| Development and distribution fee | $ 2,300,000 | ||||||
| Related consulting expense | $ 573,425 | $ 573,424 | |||||
| Consulting Agreement [Member] | |||||||
| Loss Contingencies [Line Items] | |||||||
| Management and Service Fees, Rate | 5.00% | ||||||
| License Agreements [Member] | Aquanova AG [Member] | |||||||
| Loss Contingencies [Line Items] | |||||||
| License fee | $ 75,000 | ||||||
| Royalty percentage | 1.25% | ||||||
| Royalty Expense | $ 3,000,000.0 | ||||||
| License Agreements [Member] | Aquanova AG [Member] | Minimum [Member] | |||||||
| Loss Contingencies [Line Items] | |||||||
| Other Commitment | 200,000 | ||||||
| License Agreements [Member] | Aquanova AG [Member] | Maximum [Member] | |||||||
| Loss Contingencies [Line Items] | |||||||
| Other Commitment | $ 600,000 | ||||||
| Licensing and Royalty Agreements [Member] | |||||||
| Loss Contingencies [Line Items] | |||||||
| Royalty percentage | 5.00% | ||||||
| Development milestone payments description | Pursuant to the Strategic Asset License Agreement with PharmAla, the Company is obligated to make development milestone payments totaling up to $23,333,333, consisting of (i) $3,333,333 upon first dosing of the first patient in a Phase 3 clinical trial, payable 50% in cash and 50%, at PharmAla’s election, in cash or common stock, and (ii) $20,000,000 upon first FDA approval of a New Drug Application for a licensed product, payable in cash. | ||||||
| Debt Forgiveness and Exchange Agreement [Member] | Aquanova AG [Member] | |||||||
| Loss Contingencies [Line Items] | |||||||
| Accrued license fees | $ 56,250 | $ 0 | |||||